ArticleNature2021
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 481 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
481citing papers in PubMed, 1 pooled it
44.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
481 citing papers in PubMed, 1 synthesis or guideline pooled it, 712 citations in OpenAlex.
- A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database.Human vaccines & immunotherapeutics · 2022Pooled it
- Auricular acupressure for adverse events following immunization after COVID-19 vaccine injection: A multicentre, blinded, randomized controlled trial.Complementary therapies in medicine · 2022Trial
- Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.Nature microbiology · 2022Trial
- The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination.Science translational medicine · 2022Trial
- SARS-CoV-2 Omicron infection reveals imprinted antibody responses in the absence of vaccination.iScience · 2026Article
- A novel fusion protein of COVID-19 virus enhancing protection of Syrian hamsters infected with SARS-CoV-2.Acta pharmaceutica Sinica. B · 2026Article
- Heterologous betacoronavirus spike immunization in nonhuman primates elicits cross-reactive antibodies that neutralize both sarbeco- and merbecoviruses.bioRxiv : the preprint server for biology · 2026Article
- Article
- Clonal interference and changing selective pressures shape the escape of SARS-CoV-2 from hundreds of antibodies.Virus evolution · 2026Article
- A Bibliometric Analysis on Multi-epitope Vaccine Development Against SARS-CoV-2: Current Status, Development, and Future Directions.Molecular biotechnology · 2026Review
- Article
- Mechanisms of Cell-Cell Fusion in SARS-CoV-2: An Evolving Strategy for Transmission and Immune Evasion.Viruses · 2025Review
- Structural Insights into the SARS-CoV-2 Spike Protein and Its Implications for Antibody Resistance.Biomolecules · 2025Review
- Signatures of omicron-like adaptation in early SARS-CoV-2 variants and chronic infection.Cell reports · 2025Article
- Exploring the Use of Viral Vectors Pseudotyped with Viral Glycoproteins as Tools to Study Antibody-Mediated Neutralizing Activity.Microorganisms · 2025Review
- Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial.Scientific reports · 2025Article
- Immune evasion, infectivity, and membrane fusion of the SARS-CoV-2 JN.1 variant.Virology journal · 2025Article
- Impact of SARS-CoV-2 RBM Mutations N501Y and E484K on ACE2 Binding: A Combined Computational and Experimental Study.International journal of molecular sciences · 2025Article
- Humoral responses to SARS-CoV-2 vaccine in vasculitis-related immune suppression.Science advances · 2025Article
- Mosaic vaccine design targeting mutational spike protein of SAR-SCoV-2: An immunoinformatics approach.BioImpacts : BI · 2025Article
421 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
- Update of
Authors and funding
41 authors at 20 institutions in 8 countries.
Dami A Collier *Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.ORCID http://orcid.org/0000-0001-5446-4423
Anna De Marco *Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Isabella A T M Ferreira *Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.
Bo Meng *Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.
Rawlings P Datir *Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.ORCID http://orcid.org/0000-0003-0521-2144
Alexandra C WallsDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Steven A KempCambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.
Jessica BassiHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Dora PintoHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Chiara Silacci-FregniHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Siro BianchiHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-5100-8905
M Alejandra TortoriciDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-2260-2577
John BowenDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Katja CulapHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-0956-0018
Stefano JaconiHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Elisabetta CameroniHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Gyorgy SnellVir Biotechnology, San Francisco, CA, USA.
Matteo S PizzutoHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Alessandra Franzetti PellandaClinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.
Christian GarzoniClinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.
Agostino RivaDivision of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy.ORCID http://orcid.org/0000-0003-3171-3049
CITIID-NIHR BioResource COVID-19 Collaboration
Anne ElmerNIHR Cambridge Clinical Research Facility, Cambridge, UK.
Nathalie KingstonNIHR Bioresource, Cambridge, UK.
Barbara GravesNIHR Bioresource, Cambridge, UK.
Laura E McCoyDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0001-9503-7946
Kenneth G C SmithCambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.ORCID http://orcid.org/0000-0003-3829-4326
John R BradleyDepartment of Medicine, University of Cambridge, Cambridge, UK.
Nigel TempertonUniversity of Kent, Canturbury, UK.
Lourdes Ceron-GutierrezDepartment of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.
Gabriela Barcenas-MoralesDepartment of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.
COVID-19 Genomics UK (COG-UK) Consortium
William HarveyInstitute of Biodiversity, University of Glasgow, Glasgow, UK.
Herbert W VirginVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8580-7628
Antonio LanzavecchiaHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-3041-7240
Luca PiccoliHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-1085-6502
Rainer DoffingerDepartment of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.ORCID http://orcid.org/0000-0002-9841-3617
Mark WillsDepartment of Medicine, University of Cambridge, Cambridge, UK.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-6019-8675
Davide CortiHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. dcorti@vir.bio.ORCID http://orcid.org/0000-0002-5797-1364
Ravindra K GuptaCambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK. rkg20@cam.ac.uk.ORCID http://orcid.org/0000-0001-9751-1808
Wellcome Sanger Institute · GBUniversity of Cambridge · GBPublic Health England · GBUniversity of Liverpool · GBPublic Health Wales · GBCambridge University Hospitals NHS Foundation Trust · GBUniversity College London · GBUniversity of Exeter · GBUniversity of Kent · GBUniversity of Nottingham · GBGuy's and St Thomas' NHS Foundation Trust · GBCardiff and Vale University Health Board · GBQuadram Institute · GBVir Biotechnology (Switzerland) · CHNewcastle upon Tyne Hospitals NHS Foundation Trust · GBQueen's University Belfast · GBCentre for Human Genetics · GBGreat Ormond Street Hospital for Children NHS Foundation Trust · GBRoyal Free London NHS Foundation Trust · GBUniversity Hospital Southampton NHS Foundation Trust · GB
Funding
Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeuticsDP1AI158186 · NIAID · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2020 to 2024
$5.4MAcquisition of a high resolution, high throughput cryo-electron microscopeS10OD023476 · OD · UNIVERSITY OF WASHINGTON · PI KOLLMAN, JUSTIN M · 2017 to 2017
$2.0MStructural Studies of Coronavirus Fusion ProteinsR01GM120553 · NIGMS · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2016 to 2020
$1.7MMedical Research Council MC_PC_19027Medical Research Council MR/P008801/1Medical Research Council MR/R008698/1Medical Research Council MR/S00081X/1NIAID NIH HHS DP1 AI158186NIAID NIH HHS HHSN272201700059CNIGMS NIH HHS R01 GM120553NIH HHS S10 OD023476Wellcome Trust 108082Wellcome Trust 200871/Z/16/ZWellcome Trust 204911/Z/16/Z
Abstract
Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is compounded in some areas by the higher transmission potential of the B.1.1.7 variant
Indexed as
AgedAged, 80 and overAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 SerotherapyCOVID-19 VaccinesFemaleHEK293 CellsHumansImmune EvasionImmunization, PassiveMaleMiddle AgedACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesmRNA VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, Synthetic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.